Close

LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance

Go back to LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance
(NASDAQ: LMDX) Delayed: 0.91 +0.03 (3.41%)
Previous Close $0.88    52 Week High
Open $0.91    52 Week Low
Day High $0.91    P/E N/A 
Day Low $0.87    EPS
Volume 94,502       

(NASDAQ: LMDX) Delayed: 0.91 +0.03 (3.41%)
Previous Close $0.88    52 Week High
Open $0.91    52 Week Low
Day High $0.91    P/E N/A 
Day Low $0.87    EPS
Volume 94,502